Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium
- 1 January 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 5 (1), 79-86
- https://doi.org/10.1161/circheartfailure.111.961706
Abstract
Background—: Recognizing that inhibitors of phosphodiesterase type 5 (PDE5) are increasingly employed in patients with pulmonary hypertension and right ventricular (RV) failure, we examined PDE5 expression in the human RV and its impact on myocardial contractility. Methods and Results—: Tissue extracts from the RV of 20 patients were assayed for PDE5 expression using immunoblot and immunohistochemical staining. Tissues were selected from groups of nonfailing organ donors and transplant recipients with endstage ischemic cardiomyopathy or idiopathic dilated cardiomyopathy. Among dilated cardiomyopathy patients, subgroups with mild or severe RV dysfunction and prior left ventricular assist devices were analyzed separately. Our results showed that PDE5 abundance increased more than 4-fold in the RVs of the ischemic cardiomyopathy compared with the nonfailing group. In dilated cardiomyopathy, PDE5 upregulation was more moderate and varied with the severity of RV dysfunction. Immunohistochemical staining confirmed that cardiac myocytes contributed to the upregulation in the failing hearts. In functional studies, PDE5 inhibition produced little change in developed force in RV trabeculae from nonfailing hearts but produced a moderate increase in RV trabeculae from failing hearts. Conclusions—: Our results showed the etiology- and severity-dependent upregulation of myocyte PDE5 expression in the RV and the impact of this upregulation on myocardial contractility. These findings suggest that RV PDE5 expression could contribute to the pathogenesis of RV failure, and direct myocardial responses to PDE5 inhibition may modulate the indirect responses mediated by RV afterload reduction.This publication has 28 references indexed in Scilit:
- Structure and function of cyclic nucleotide-gated channelsReviews of physiology, biochemistry and pharmacology, 2005
- Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and ApoptosisPublished by Elsevier BV ,2005
- Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophyNature Medicine, 2005
- cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent MechanismCirculation Research, 2005
- Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin TBMC Pharmacology, 2005
- Adaptive and maladaptive hypertrophic pathways: points of convergence and divergenceCardiovascular Research, 2004
- Tissue expression, distribution, and regulation of PDE5International Journal of Impotence Research, 2004
- Phosphorylation of phosphodiesterase‐5 by cyclic nucleotide‐dependent protein kinase alters its catalytic and allosteric cGMP‐binding activitiesJBIC Journal of Biological Inorganic Chemistry, 2000
- Cyclic GMP Phosphodiesterase-5: Target of SildenafilPublished by Elsevier BV ,1999
- Recommendations for Quantitation of the Left Ventricle by Two-Dimensional EchocardiographyJournal of the American Society of Echocardiography, 1989